| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ACTL6A; BAF53; BAF53A; INO80K; Actin-like protein 6A; 53 kDa BRG1-associated factor A; Actin-related protein Baf53a; ArpNbeta; BRG1-associated factor 53A; BAF53A; INO80 complex subunit K |
| Entrez GeneID | 86 |
| WB Predicted band size | Calculated MW: 47 kDa; Observed MW: 47 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human ACTL6A |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
1. **"ACTL6A regulates histone H3K27 acetylation and promotes leukemogenesis"**
*Author: Wang et al.*
摘要：研究揭示了ACTL6A通过调控组蛋白H3K27乙酰化影响染色质重塑，在急性髓系白血病中促进肿瘤细胞增殖，研究中使用了ACTL6A抗体进行ChIP-seq和Western blot验证。
2. **"ACTL6A maintains tumorigenicity of oral squamous cell carcinoma via YAP/TAZ signaling"**
*Author: Li et al.*
摘要：该文献证明ACTL6A通过调控Hippo-YAP/TAZ通路驱动口腔鳞癌进展，利用ACTL6A抗体进行免疫组化和功能缺失实验，表明其可作为潜在治疗靶点。
3. **"ACTL6A is required for neural progenitor differentiation and cortical development"**
*Author: Smith et al.*
摘要：研究通过小鼠模型和ACTL6A抗体染色发现，该蛋白在神经前体细胞分化中起关键作用，缺失导致皮层发育异常，提示其在神经疾病中的潜在机制。
4. **"The BAF complex component ACTL6A protects against squamous carcinogenesis"**
*Author: Hota et al.*
摘要：研究发现皮肤上皮细胞中ACTL6A缺失导致BAF复合体功能障碍，促进鳞状细胞癌变，通过抗体介导的蛋白互作分析揭示了其抑癌分子机制。
ACTL6A (Actin-like 6A), also known as BAF53A, is a subunit of the multiprotein BAF (BRG1/BRM-associated factor) chromatin remodeling complex, which regulates gene expression by altering chromatin structure through ATP-dependent mechanisms. As part of the SWI/SNF family, it plays critical roles in cellular processes including differentiation, proliferation, and DNA repair. ACTL6A is highly conserved and expressed ubiquitously, with essential functions in embryonic development and tissue-specific gene regulation. Dysregulation of ACTL6A has been linked to cancers, neurodevelopmental disorders (e.g., Coffin-Siris syndrome), and other diseases.
Antibodies targeting ACTL6A are widely used in research to study its expression, localization, and interactions. They enable detection via techniques like Western blotting, immunofluorescence, immunohistochemistry, and chromatin immunoprecipitation (ChIP). Many commercially available ACTL6A antibodies are raised against specific epitopes in human or murine ACTL6A, with validation in knockout/knockdown models to confirm specificity. These tools are vital for exploring ACTL6A's role in chromatin remodeling, its partnership with other BAF subunits (e.g., BRG1. BAF155), and its involvement in disease pathways. Researchers also utilize these antibodies to investigate therapeutic targets in oncology and developmental biology, particularly in contexts where ACTL6A overexpression or loss correlates with clinical outcomes.
×
